as on October 24, 2025 at 1:29 am IST
Day's High
4.17%
Upside
52 Week's Low
52 Week's High
1.46%
Downside
481.25%
Upside
Check Can Fite Biopharma Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$15.4M
EPS (TTM)
-0.52
Dividend Yield
0.00%
PE Ratio (TTM)
0PEG Ratio
0Return On Equity TTM
-264.12%
Compare market cap, revenue, PE, and other key metrics of Can Fite Biopharma Ltd with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
NA | $15.4M | -97.13% | NA | 0.00% | |
BUY | $63.1B | 252.62% | -505.15 | -12.96% | |
NA | $35.3B | NA | NA | -3.89% | |
BUY | $109.3B | 101.55% | 30.36 | 31.86% | |
BUY | $61.3B | 0.85% | 14.6 | 31.37% |
The Can Fite Biopharma Ltd stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Can Fite Biopharma Ltd investment value today
Current value as on today
₹22,766
Returns
Returns from Can Fite Biopharma Ltd Stock
Dollar Returns*
₹4,653 (+4.65%)
Search interest for Can Fite Biopharma Ltd Stock has increased by 48% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:48% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 133.8% return, outperforming this stock by 227.1%
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 57.7% return, outperforming this stock by 138.9%
Price Dip
In the last 1 month, CANF stock has moved down by -20.7%
Revenue Fall
Revenue is down for the last 3 quarters, 179.0K → 101.0K (in $), with an average decrease of 21.8% per quarter
Profit Down
Netprofit is down for the last 3 quarters, -1.96M → -2.43M (in $), with an average decrease of 12.2% per quarter
Organisation | Can Fite Biopharma Ltd |
Headquarters | 26 Ben Gurion Street, Ramat Gan, Israel, 5257346 |
Industry | Health Technology |
CEO | Mr. Motti Farbstein |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Dr. Sari Fishman Ph.D. | Vice President of Business Development |
Dr. Stephen A. Harrison FACP, M.D. | Member of Clinical Advisory Board & Consulting Chief Medical Officer |
Dr. Pnina Fishman Ph.D. | Founder, Chief Scientific Officer & Executive Chairperson |
Mr. Motti Farbstein | CEO and Chief Financial & Operating Officer |
Can Fite Biopharma Ltd share price today is $0.48 as on at the close of the market. Can Fite Biopharma Ltd share today touched a day high of $0.5 and a low of $0.48.
Can Fite Biopharma Ltd share touched a 52 week high of $2.79 on and a 52 week low of $0.47 on . Can Fite Biopharma Ltd stock price today i.e. is closed at $0.48,which is 82.80% down from its 52 week high and 1.48% up from its 52 week low.
Can Fite Biopharma Ltd market capitalisation is $0.00T as on .
Indian investors can start investing in Can Fite Biopharma Ltd (CANF) shares with as little as ₹87.835 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.35 in Can Fite Biopharma Ltd stock (as per the Rupee-Dollar exchange rate as on ).
Based on Can Fite Biopharma Ltd share’s latest price of $0.48 as on October 24, 2025 at 1:29 am IST, you will get 20.8333 shares of Can Fite Biopharma Ltd. Learn more about
fractional shares .
Can Fite Biopharma Ltd stock has given -97.13% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?